Skip to main content
Erschienen in: Diabetologia 11/2010

01.11.2010 | Short Communication

Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986–2006 in Sweden

verfasst von: R. Marsk, E. Jonas, F. Rasmussen, E. Näslund

Erschienen in: Diabetologia | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Symptomatic hypoglycaemia with related confusion, syncope, epilepsy or seizures is a newly recognised complication of gastric bypass surgery for obesity. The incidence of these conditions is not known. We therefore studied the incidence of post-gastric bypass hypoglycaemia and related symptoms in patients who have undergone gastric bypass and a reference cohort from the general population of Sweden.

Methods

This is a nationwide cohort study based on national registries with 5,040 persons who underwent gastric bypass, vertical banded gastroplasty or gastric banding for obesity in Sweden between 1 January 1986 and 31 December 2006 and a cohort of ten referents per patient matched for sex and age randomly sampled from the general population. The incidence rates of hospitalisation for hypoglycaemia, confusion, syncope, epilepsy or seizures before and after dates of surgery or inclusion in the reference cohort were studied.

Results

Preoperative incidences of hospitalisation for hypoglycaemia were similar in the surgical and referent cohorts. After gastric bypass surgery, the adjusted hazard ratios were significantly elevated for hypoglycaemia (2.7 [95% CI 1.2–6.3]), confusion (2.8 [1.3–6.0]), syncope (4.9 [3.4–7.0]), epilepsy (3.0 [2.1–4.3]) and seizures (7.3 [5.0–10.8]). The proportions of gastric bypass patients and reference participants affected by hypoglycaemia were very low (0.2% and 0.04%, respectively). There was no increased risk of hypoglycaemia after vertical banded gastroplasty or gastric banding compared with the referent population.

Conclusions/interpretation

Obese persons who have undergone gastric bypass have an increased risk of hospitalisation for diagnoses associated with post-gastric bypass hypoglycaemia, although few patients are affected.
Literatur
1.
Zurück zum Zitat Sjöström L, Lindroos AK, Peltonen M et al (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683–2693CrossRefPubMed Sjöström L, Lindroos AK, Peltonen M et al (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683–2693CrossRefPubMed
2.
Zurück zum Zitat Le Roux CW, Welbourn R, Werling M et al (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:780–785CrossRefPubMed Le Roux CW, Welbourn R, Werling M et al (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:780–785CrossRefPubMed
3.
Zurück zum Zitat Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV (2005) Hyperinsulinemic hypoglycemia with nesidoblastosis after gastric-bypass surgery. N Engl J Med 252:249–254CrossRef Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV (2005) Hyperinsulinemic hypoglycemia with nesidoblastosis after gastric-bypass surgery. N Engl J Med 252:249–254CrossRef
4.
Zurück zum Zitat Patti ME, McMahon C, Mun EC et al (2005) Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240CrossRefPubMed Patti ME, McMahon C, Mun EC et al (2005) Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240CrossRefPubMed
5.
Zurück zum Zitat Goldfine AB, Mun EC, Devine E et al (2007) Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol 92:4678–4685CrossRef Goldfine AB, Mun EC, Devine E et al (2007) Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol 92:4678–4685CrossRef
6.
Zurück zum Zitat Clancy TE, Moore FD Jr, Zinner MJ (2006) Post-gastric bypass hyperinsulinism with nesidoblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 10:1116–1119CrossRefPubMed Clancy TE, Moore FD Jr, Zinner MJ (2006) Post-gastric bypass hyperinsulinism with nesidoblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 10:1116–1119CrossRefPubMed
7.
Zurück zum Zitat Vella A, Service FJ (2007) Incretin hypersecretion in post-gastric bypass hypoglycemia—primary problem or red herring? J Clin Endocrinol Metab 92:4563–4565CrossRefPubMed Vella A, Service FJ (2007) Incretin hypersecretion in post-gastric bypass hypoglycemia—primary problem or red herring? J Clin Endocrinol Metab 92:4563–4565CrossRefPubMed
8.
Zurück zum Zitat Kellogg TA, Bantle JP, Leslie DB et al (2008) Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 4:492–499CrossRefPubMed Kellogg TA, Bantle JP, Leslie DB et al (2008) Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 4:492–499CrossRefPubMed
9.
Zurück zum Zitat Meier JJ, Butler AE, Galasso R, Butler PC (2006) Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 29:1554–1559CrossRefPubMed Meier JJ, Butler AE, Galasso R, Butler PC (2006) Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 29:1554–1559CrossRefPubMed
10.
Zurück zum Zitat Ukleja A (2005) Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract 20:517–525CrossRefPubMed Ukleja A (2005) Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract 20:517–525CrossRefPubMed
11.
Zurück zum Zitat Yamamoto H, Mori T, Tsuchihashi H, Akabori H, Naito H, Tani T (2005) A possible role of GLP-1 in the pathophysiology of early dumping syndrome. Dig Dis Sci 50:2263–2267CrossRefPubMed Yamamoto H, Mori T, Tsuchihashi H, Akabori H, Naito H, Tani T (2005) A possible role of GLP-1 in the pathophysiology of early dumping syndrome. Dig Dis Sci 50:2263–2267CrossRefPubMed
Metadaten
Titel
Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986–2006 in Sweden
verfasst von
R. Marsk
E. Jonas
F. Rasmussen
E. Näslund
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 11/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1798-5

Weitere Artikel der Ausgabe 11/2010

Diabetologia 11/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.